



FemmePharma
GLOBAL HEALTHCARE, INC.

FEMMEPHARMA, INC. JOINS CORPORATE ADVISORY BOARD OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION

June 17, 2003

WAYNE, PA - FemmePharma has recently accepted an invitation to join the Corporate Advisory Board of the Society for Gynecologic Investigation (SGI). The mission of SGI is to establish a scientific basis for gynecology, obstetrics and related disciplines by providing and promoting the following:

- Leadership and excellence in research;
- International forums for scientific exchange;
- Mentoring, career development and education;
- Advocacy for research in women's health and reproductive science; and
- Collaboration with academia, government and industry.

Jerome F. Strauss, III, MD, Ph.D. serves as the President of SGI. He is Associate Chairman of Obstetrics and Gynecology at the University of Pennsylvania and is the Director of the Institute for the Study of Women. He is internationally recognized for his work in reproductive endocrinology and has published extensively in the area of control of the reproductive cycle.

FemmePharma was formed by Gerianne Tringali-DiPiano in 1996 to target identifiable unmet needs within the estimated \$35 billion women's healthcare pharmaceutical market. The company has a number of drugs in development based on its proprietary PARDEL™ technology. The founding of FemmePharma by Tringali-DiPiano followed her extensive experience in key positions with several large women's healthcare pharmaceutical companies.

For more information on FemmePharma, call Kim Groff at (610) 995-0801 or visit www.fpghc.com.

###